Not currently recruiting at UC Davis

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

a study on Transitional Cell Carcinoma Bladder Cancer Urinary Bladder Tumor Neoplasm Metastasis FGFR Gene Alteration

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Sacramento, California and other locations
Dates
study started
study ends around
Principal Investigator
by Mamta Parikh

Description

Summary

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread.

Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab.

Study participation could last up to approximately 6 years.

Official Title

FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration

Keywords

Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis, FGFR3, Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Transitional Cell Carcinoma, pembrolizumab, Vepugratinib, Vepugratinib + EV + Pembrolizumab (Safety Lead In), Vepugratinib + Enfortumab Vedotin (EV) + Pembrolizumab

Eligibility

You can join if…

Open to people ages 18 years and up

  • Have histologically confirmed, unresectable locally advanced or metastatic urothelial cancer (mUC). Individuals with mixed histology other than small cell or neuroendocrine carcinoma are eligible if a urothelial component is present.
  • Have a qualifying fibroblast growth factor receptor 3 (FGFR3) genetic alteration determined via molecular testing from a tumor or blood sample obtained at or any time after diagnosis of advanced or metastatic urothelial cancer.
  • Have measurable disease by investigator assessment defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  • Have adequate laboratory parameters

You CAN'T join if...

  • Have received prior systemic therapy for locally advanced or metastatic urothelial cancer (mUC).
  • Have any unresolved toxicities greater than Grade 1 Common Terminology Criteria for Adverse Events ([CTCAE] version 5.0) from prior neoadjuvant or adjuvant systemic therapy.
  • Have ongoing sensory or motor neuropathy of Grade 2 or higher
  • Have untreated or uncontrolled central nervous system (CNS) involvement or any history of leptomeningeal disease.
  • Current evidence corneal keratopathy or retinal disorder confirmed by ocular examination at screening.

Locations

  • University of California Davis (UC Davis) Comprehensive Cancer Center not yet accepting patients
    Sacramento California 95817 United States
  • UCSF Medical Center at Mission Bay accepting new patients
    San Francisco California 94158 United States
  • Hunt Cancer Institute, an Affiliate of Cedars-Sinai Cancer (TMPN) accepting new patients
    Torrance California 90505 United States

Lead Scientist at UC Davis

  • Mamta Parikh
    I am a clinical researcher focusing on genitourinary malignancies, with a growing interest in cancer research education.

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
Lilly Trials site
ID
NCT07218380
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 450 study participants
Last Updated